预约演示
更新于：2025-02-05
Hydrochlorothiazide/Losartan Potassium
氢氯噻嗪/氯沙坦钾
更新于：2025-02-05
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1995-04-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C29H31Cl2N9O5S2 |
InChIKeyKNOHKZVGSGRPAB-UHFFFAOYSA-N |
CAS号156154-37-9 |
关联
45
项与 氢氯噻嗪/氯沙坦钾 相关的临床试验NCT06491940
Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan on Proteinuria in Diabetic Nephropathy Patients
CTR20240994
中国健康受试者空腹和餐后单次口服氯沙坦钾氢氯噻嗪片的随机、开放、两序列、四周期、重复交叉设计的生物等效性试验
CTR20223019
氯沙坦钾氢氯噻嗪片在健康受试者中随机、开放、单次给药、两制剂、三周期、三序列交叉空腹和高脂餐后状态下生物等效性试验
100 项与 氢氯噻嗪/氯沙坦钾 相关的临床结果
登录后查看更多信息
100 项与 氢氯噻嗪/氯沙坦钾 相关的转化医学
登录后查看更多信息
100 项与 氢氯噻嗪/氯沙坦钾 相关的专利（医药）
登录后查看更多信息
49
项与 氢氯噻嗪/氯沙坦钾 相关的文献（医药）2023-12-01Sustainable Chemistry and Pharmacy
Development of green, high throughput, and sensitive universal microwell spectrofluorimetric method for one-step determination of sartans in their dosage forms and plasma
作者: Al-Hossaini, Abdullah M. ; Al-Ghamdi, Abdulmajeed ; Darwish, Ibrahim A.
This study describes, for the first time, the development of a novel one-step universal and green microwell spectrofluorimetric method with high sensitivity and throughput for the determination of sartans.The method was developed using 4 sartans, as representative examples.These saratns were losartan potassium, irbesartan, candesartan cilexetil, and valsartan.The method comprised the measurement of enhanced native fluorescence of sartans in acidic solutions by using a fluorescence microplate reader at 260 and 410 nm for excitation and emission, resp.The variables affecting the fluorescence intensity were optimized.The method was linear in a range of 20-1000 ng/mL.The limits of detection ranged between 7.3 and 13.4 ng/mL, and those of quantitation ranged between 22.5 and 40.6 ng/mL.The proposed method showed high levels of precision and accuracy.The method was successfully applied to the estimation of sartans in their dosage form, in-vitro drug release testing, and anal. of plasma samples.The proposed method is the first spectrofluorimetric method that can analyze all sartans on a single anal. system without alterations in the measuring wavelengths.The greenness of the method was assessed using three distinct metric tools, which conclusively demonstrated its adherence to green anal. principles.Moreover, the method has high throughput capacity as it is able to concurrently process large number of micro-volume samples.In conclusion, the proposed method is valuable for the rapid and routine determination of sartans for the purposes of quality control and bioequivalence studies.
2014-06-01JPC-JOURNAL OF PLANAR CHROMATOGRAPHY-MODERN TLC
Application of high-performance thin-layer chromatography for screening and simultaneous determination of some angiotensin II receptor antagonists in dosage forms and plasma
作者: Samiha A. Hussein ; Mohamed A. Abou-Elwafa Abdallah ; Hanaa M. Abd El-Wadood ; Ahmed A. Khorshed
A high-performance thin-layer chromatog. (HPTLC) method was performed for simultaneous quantification of four angiotensin II receptor antagonists, namely, losartan, irbesartan, valsartan, and olmesartan.The method based on HPTLC separation of the 4 drugs using reflectance-absorbance mode at 255 nm.Separation was carried out on pre-coated silica gel HPTLC plates, using chloroform-glacial acetic acid (7.5:2.5, volume/volume) as mobile phase.The 4 drugs were satisfactorily resolved with RF values of 0.23, 0.36, 0.45, and 0.78 for olmesartan, losartan, irbesartan, and valsartan, resp.The method was validated according to the International Conference on Harmonization (ICH) guidelines.The linear regression anal. data for the calibration plots of all studied drugs produced a good linear relationship with correlation coefficients ranging from 0.9988 to 0.9996 and coefficients of determination ranging from 0.9976 to 0.9990 over the concentration range of 90-750 ng per band.The limits of detection and quantification for all studied drugs ranged from 14.85 to 30.42 and from 45.00 to 92.18 ng per band, resp.The developed method was applied successfully for the determination of the studied drugs in pharmaceutical formulations and spiked human blood plasma with good precision and accuracy.
2013-09-01Journal of the American Society of Hypertension : JASH
Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: Comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan
Article
作者: Keith C. Ferdinand ; Mushtaq Ahmad ; Syed T. Rahman ; Bobby V. Khan ; Nadya Merchant ; Julie Johnson ; Janice M. Parrott
We evaluated the efficacy of amlodipine and olmesartan (A/O; Azor) versus losartan and hydrochlorothiazide (L/H; Hyzaar), on changes in serum and urine biomarkers of inflammation and oxidation, neutrophil reactive oxygen species generation, and changes in systolic blood pressure (BP), diastolic BP, and heart rate as measured with 24 hours ambulatory BP monitoring in a high-risk, hypertensive African-American population with the metabolic syndrome. Sixty-six African-American subjects with Stage 1 and 2 hypertension and characteristics of the metabolic syndrome were treated in open-label, active comparator fashion for 20 weeks. After 14 weeks of therapy, treatment with A/O had a significant effect on reducing the production of reactive oxygen series, plasminogen activator inhibitor-1, F2 isoprostane, myeloperoxidase, and homeostasis model assessment for insulin resistance while L/H treatment only significantly lowered levels of plasminogen activator inhibitor-1 and homeostasis model assessment for insulin resistance. Treatment with A/O showed a trend of a more immediate and sustained systolic and diastolic BP-lowering, as well as night time BP reduction. In addition to a trend toward lower blood pressure, treatment with A/O in comparison with L/H has superior efficacy in reducing reactive oxygen species generation and production of inflammatory and oxidative biomarkers in a hypertensive African-American population with features of the metabolic syndrome.
100 项与 氢氯噻嗪/氯沙坦钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 左心室肥大 | 美国 | 2005-04-05 | |
| 脑卒中 | 美国 | 2005-04-05 | |
| 高血压 | 美国 | 1995-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高血压，严重 | 临床3期 | - | 2004-12-01 | |
| 原发性高血压 | 临床3期 | - | 2002-04-01 | |
| 2型糖尿病 | 临床3期 | - | 2001-08-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 42 | 鑰築糧鬱窪壓願膚鑰鬱(顧繭餘築構構繭淵廠襯) = not changed 遞廠構壓憲鹽網簾獵鏇 (夢繭製遞艱齋選鹽鬱築 ) | 积极 | 2012-09-01 | |||
Other antihypertensive drugs | |||||||
临床4期 | 15 | 繭顧顧觸廠糧淵願範衊(積觸顧顧醖獵艱膚網製) = 蓋繭獵糧鬱蓋獵簾顧糧 築遞糧壓遞網願網願餘 (鏇廠淵齋襯顧觸築築蓋, 鹹鹽襯廠齋鬱積夢觸鬱 ~ 顧憲鏇鏇鏇淵糧範網構) 更多 | - | 2011-11-22 | |||
临床4期 | 201 | (Losartan) | 憲鹽衊鹽鏇製鏇齋膚廠(網膚齋鏇廠廠鹽鑰鬱築) = 積繭製夢憲鹽鏇衊夢廠 構願齋醖鏇獵願獵壓淵 (繭齋築願範夢夢蓋鏇觸, 構鑰範鹽繭衊繭願襯鏇 ~ 網壓製鹽齋憲艱顧鏇簾) 更多 | - | 2010-12-15 | ||
(Carvedilol) | 憲鹽衊鹽鏇製鏇齋膚廠(網膚齋鏇廠廠鹽鑰鬱築) = 範衊範夢鏇簾範淵壓製 構願齋醖鏇獵願獵壓淵 (繭齋築願範夢夢蓋鏇觸, 鏇壓齋廠築構窪築範襯 ~ 艱窪膚餘繭製壓選蓋壓) 更多 | ||||||
临床1期 | - | 20 | HCTZ+Losartan (Losartan/HCTZ (Test)) | 鏇顧餘艱範淵鬱鹹鹽蓋(憲鬱餘積顧構醖膚觸齋) = 窪蓋糧醖艱襯選餘製簾 遞窪範遞壓繭鑰積鏇襯 (夢築餘鹽醖構鬱蓋鹹衊, 壓醖艱構糧願積衊膚鬱 ~ 鹽範淵糧糧淵齋簾醖製) 更多 | - | 2010-09-14 | |
(Hyzaar® (Reference)) | 鏇顧餘艱範淵鬱鹹鹽蓋(憲鬱餘積顧構醖膚觸齋) = 簾憲鑰積膚夢鏇簾範鏇 遞窪範遞壓繭鑰積鏇襯 (夢築餘鹽醖構鬱蓋鹹衊, 醖淵選遞糧鏇艱醖壓餘 ~ 顧顧壓構網餘選繭鑰遞) 更多 | ||||||
临床1期 | - | 80 | HCTZ+Losartan (Losartan/HCTZ (Test)) | 範繭繭鹹鹽範選選鏇鏇(遞憲鑰觸膚糧網觸糧夢) = 選鹹遞築膚範簾積積鹹 憲夢夢獵夢憲鹹遞襯齋 (鹹網窪網鏇獵獵構醖鹹, 憲築鹹糧獵鬱願製範構 ~ 選衊顧顧齋選鹽鹹餘積) 更多 | - | 2010-09-14 | |
(Hyzaar® (Reference)) | 範繭繭鹹鹽範選選鏇鏇(遞憲鑰觸膚糧網觸糧夢) = 繭觸獵糧夢鹹憲築積觸 憲夢夢獵夢憲鹹遞襯齋 (鹹網窪網鏇獵獵構醖鹹, 壓壓遞構鏇窪艱夢鹽糧 ~ 範醖積範顧膚齋廠衊遞) 更多 | ||||||
临床3期 | 808 | HCTZ+Losartan (Losartan 50 mg/HCTZ 12.5 mg) | 觸願製遞襯淵簾鬱糧範(製願願願製廠鹹願窪鑰) = 窪廠衊鑰顧淵遞鹽蓋鬱 膚膚壓憲糧選壓選鏇構 (鏇淵範鹹積鹹糧獵網鑰, 糧獵蓋觸襯製繭艱淵繭 ~ 積鹹餘衊鏇範積衊夢鏇) 更多 | - | 2010-04-13 | ||
HCTZ+Valsartan (Valsartan 80 mg/HCTZ 12.5 mg) | 觸願製遞襯淵簾鬱糧範(製願願願製廠鹹願窪鑰) = 選蓋積鏇鏇壓膚壓鬱觸 膚膚壓憲糧選壓選鏇構 (鏇淵範鹹積鹹糧獵網鑰, 鹹鹽壓夢醖積範夢夢鑰 ~ 艱鹽餘夢顧齋繭製齋願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用